Stephen Mullin PhD

Stephen Mullin is a neurologist and clinical academic with a research interest in Parkinson's disease. Her primary interest is the genetic and clinical stratification of the risk of Parkinson's disease by targeting novel neuroprotective compounds. He also has expertise in clinical trial design and implementation and internet-based clinical assessment in Parkinson's disease.

Stephen Mullin's majority of research has centered on the glucocerebrosidase (GBA) pathway, numerically the most significant genetic risk factor for Parkinson's disease. This included the day-to-day running of phase II clinical trial of ambroxol, a putative neuroprotective and small molecular chaperone of the glucocerebrosidase enzyme (GCase). Additionally, He jointly runs an internet-based cohort study, Rapsodi (http://rapsodistudy.com), which aims to stratify GBA mutation carriers without Parkinson's disease in terms of their disease risk using clinical, genetic, and biochemical parameters. He also runs a http://pdfrontline.com, a portal for genotyping of those with Parkinson's disease for GBA and LRRK2. The ultimate of these studies is to provide a cost-effective platform for targeting future neuroprotective compounds.

Stephen Mullin has a burgeoning interest in the use of machine learning and artificial intelligence to improve care, solve clinical problems and answer the mechanistic questions in relation to Parkinson's and other disease areas. He heads an ongoing project which aims to use routine imaging data, collected from across the South West Peninsula, to develop novel biomarkers for the development of Parkinson's.